Jul 31, 2019
DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)
Jul 30, 2019
Significant Regulatory Milestone Towards Phase 2 in Recurrent GBM
Jul 24, 2019
DelMar Pharmaceuticals Enrolls First Patient in the Recently-Approved Adjuvant Setting Arm of Phase 2 Study of VAL-083 for the Treatment of MGMT-Unmethylated Glioblastoma Multiforme
Jul 12, 2019
Global Adult Malignant Glioma Therapeutics Market Research Report 2019-2024: Merck & Co, Roche, and Pfizer Lead the Competition
Jul 12, 2019
Global Brain Tumor Therapeutics Market Outlook Report, 2019-2024 - Immunotherapy Expected to Register Robust Growth
Jun 18, 2019
Mill Creek Life Sciences Receives Grant from Regenerative Medicine Minnesota for Development of Dendritic Cell Vaccine
Jun 18, 2019
Beactica Wins Grant to Develop Combination Therapy for Glioblastoma
Jun 18, 2019
Medicenna Presents Preliminary Top-Line Clinical Results from their Phase 2b Trial of MDNA55 in Recurrent Glioblastoma
Jun 13, 2019
Medicenna To Host Key Opinion Leader Call Focused on MDNA55 Recurrent Glioblastoma Program and Preliminary Top-Line Results
Jun 04, 2019
Beactica Secures Another Round of Financing as Novel Glioblastoma Treatment Advances Towards Pre-clinical Development
Jun 03, 2019
DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 03, 2019
Medicenna Presents Clinical Validation of the IL4 Receptor as a Biomarker for MDNA55 in Recurrent Glioblastoma
May 20, 2019
Three DB102 (Enzastaurin) Presentations at ASCO and the 15th International Conference on Malignant Lymphoma (ICML)
May 20, 2019
DelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board
May 17, 2019
AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer
May 16, 2019
Medicenna Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 08, 2019
New positive data from phase IIa trial in brain cancer patients
May 01, 2019
Medicenna Receives Non-Dilutive Grant Payment
Apr 30, 2019
Medicenna Announces Completion of Enrolment in MDNA55 Phase 2b Recurrent Glioblastoma Clinical Study
Apr 11, 2019
Higher Oxygen Levels Could Increase Effectiveness of New Line of Brain Cancer-Killing Drugs